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Introduction
Tuberous sclerosis complex (TSC), caused by loss of function 
of either the TSC1 or -2 tumor suppressor genes, is an auto-
somal dominant disorder that leads to mental retardation, sei-
zures, and the formation of tumors in various organs, including 
the brain, kidney, heart, and skin (Young and Povey, 1998; 
Gomez et al., 1999; Cheadle et al., 2000). The TSC1 gene en-
codes the 130-kD protein hamartin (van Slegtenhorst et al., 
1997), and the TSC2 gene encodes the 198-kD protein tuberin 
(The European Chromosome 16 Tuberous Sclerosis Consor-
tium, 1993). Hamartin contains two coiled-coil domains, 
which have been shown to mediate binding to tuberin (Hodges 
et al., 2001), forming a stable, functional tumor suppressor 
heterodimer within cells (Plank et al., 1998; van Slegtenhorst 
et al., 1998). Lesions that develop in TSC patients are histo-
logically diverse; however, the tumors that arise as a result of 
loss of function of either TSC1 or -2 share common features, 
suggesting that hamartin and tuberin function within the same 
pathways to regulate cell cycle, cell growth, adhesion, and 
vesicular traffi  cking (van Slegtenhorst et al., 1998; Hengstschlager 
et al., 2001).   Recent studies have indicated that the hamartin–
tuberin   heterodimer regulates cell growth and proliferation as 
a downstream component of the phosphoinositide 3-kinase 
(PI3K)–protein kinase B (PKB/AKT) signaling pathway, 
which modulates signal transduction through target of 
  rapamycin (TOR) in both Drosophila melanogaster and 
  mammalian cells (Manning and Cantley, 2003; Inoki et al., 
2005). Several distinct yet complementary genetic and bio-
chemical studies collectively show that tuberin is a GTPase-
activating protein (GAP) for the small GTPase Ras homologue 
enriched in brain (Rheb), which activates TOR and its down-
stream   targets, such as the ribosomal S6 kinase (RSK; Li 
et al., 2004a).
Although loss of tuberin promotes cell growth and 
  tumorigenesis, cells expressing tuberin must also be able to 
relieve tuberin repression of mammalian TOR (mTOR) sig-
naling during conditions of mitogenic suffi  ciency. In this re-
gard, tuberin contains multiple sites for AKT, MAPK, RSK, 
and extracellular signal–regulated kinase phosphorylation 
(Dan et al., 2002; Liu et al., 2002; Manning et al., 2002; Li 
et al., 2003; Tee et al., 2003; Roux et al., 2004; Ballif et al., 
2005). Although it is clear that activation of AKT blocks tu-
berin inhibition of TOR signaling (Inoki et al., 2002;   Manning 
et al., 2002; Potter et al., 2002), the mechanism by which 
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oss of tuberin, the product of TSC2 gene, increases 
mammalian target of rapamycin (mTOR) signaling, 
promoting cell growth and tumor development. 
  However, in cells expressing tuberin, it is not known how 
repression of mTOR signaling is relieved to activate this 
pathway in response to growth factors and how hamartin 
participates in this process. We show that hamartin co-
localizes with hypophosphorylated tuberin at the mem-
brane, where tuberin exerts its GTPase-activating protein 
(GAP) activity to repress Rheb signaling. In response to 
growth signals, tuberin is phosphorylated by AKT and 
translocates to the cytosol, relieving Rheb repression. 
Phosphorylation of tuberin at serines 939 and 981 does 
not alter its intrinsic GAP activity toward Rheb but parti-
tions tuberin to the cytosol, where it is bound by 14-3-3 
proteins. Thus, tuberin bound by 14-3-3 in response 
to AKT phosphorylation is sequestered away from its 
  membrane-bound activation partner (hamartin) and its 
target GTPase (Rheb) to relieve the growth inhibitory ef-
fects of this tumor suppressor.
Correspondence to Cheryl Lyn Walker: cwalker@wotan.mdacc.tmc.edu
Abbreviations used in this paper: CIAP, calf intestinal alkaline phosphatase; 
GAP, GTPase-activating protein; IGF-1, insulin-like growth factor-1; mTOR, mam-
malian TOR; PI3K, phosphoinositide 3-kinase; Rheb, Ras homologue enriched 
in brain; RSK, ribosomal S6K; S6K, S6 kinase; TOR, target of rapamycin; TSC, 
tuberous sclerosis complex.
The online version of this paper contains supplemental material.
LJCB • VOLUME 173 • NUMBER 2 • 2006  280
AKT   inactivates this tumor suppressor is unknown (Bjornsti 
and Houghton, 2004). In addition, there are confl  icting data re-
garding the subcellular localization of tuberin. For instance, in-
dependent studies report that tuberin can localize to the cytosol 
(Nellist et al., 1999), the membrane/particulate (100,000 g) 
fraction (Wienecke et al., 1995), and even the nucleus (Lou 
et al., 2001) of cells.
In this study, we sought to determine the mechanisms by 
which tuberin is regulated during cell growth. We found that 
  tuberin is localized in membrane and cytosol fractions but not 
in nuclear fractions, and the translocation of tuberin from the 
membrane to cytosol is regulated by AKT signaling in response 
to growth factors. Phosphorylation of tuberin by AKT causes 
tuberin to become sequestered by 14-3-3 proteins in the cytosol. 
Mutation of two specifi  c phosphorylation sites (S939 and S981) 
prevents the cytosolic translocation of tuberin from cellular 
membranes and results in a constitutively active protein that 
  inhibits mTOR signaling. Importantly, tuberin phosphorylation 
by AKT does not affect its GAP activity toward Rheb in vitro 
but promotes Rheb-induced S6 kinase (S6K) 1 activation 
through increased Rheb-GTP loading in vivo. Therefore, it is 
likely that AKT phosphorylation inhibits tuberin as a result of 
14-3-3 binding and cytosolic translocation rather than by im-
pairing its catalytic GAP activity.
Results
Tuberin localization is regulated by Ser/Thr 
phosphorylation in response to growth 
factor stimulation
To investigate the subcellular localization of tuberin, mouse 
 fi broblast (NIH3T3, Swiss3T3), rat kidney epithelial (TRKE2), 
human embryonic kidney (HEK293), and human breast cancer 
(MCF7) cell lines were fractionated, revealing that tuberin was 
detected within both the cytosolic and membrane fractions but 
not within the nuclear fraction (Fig. 1 A). Interestingly, tuberin 
in the membrane fraction migrated faster than tuberin within the 
cytosolic fraction (Fig. 1 A).
To determine whether this mobility shift was due to 
changes in phosphorylation, we treated these subcellular frac-
tions with either a Ser/Thr or Tyr phosphatase (calf intestinal 
alkaline phosphatase [CIAP] or YOP protein tyrosine phospha-
tase, respectively). After CIAP treatment, the mobility of tuberin 
in the cytosol increased, resolving as a faster migrating band 
similar to tuberin purifi  ed from membrane fractions (Fig. 1 B). 
However, YOP did not affect tuberin mobility, indicating that the 
mobility shift was primarily due to phosphorylation of Ser/Thr 
residues. Treatment with CIAP resulted in both membrane and 
cytosolic tuberin migrating faster, indicating that   tuberin within 
Figure 1.  Tuberin localization is determined 
by Ser/Thr phosphorylation. (A) Western an-
alyses of subcellular fractions from the indi-
cated cell lines using an anti-tuberin antibody. 
β1-integrin and lamin A/C proteins were 
  analyzed as fractionation controls. Similar re-
sults were also observed with canine kidney 
cell lysates (not depicted). (B) Fractionated 
NIH3T3 lysates were treated with either CIAP 
serine/threonine phosphatase or YOP tyro-
sine phosphatase at 30°C for 1 h, and the 
electrophoretic mobility of tuberin was deter-
mined by Western analysis. (C) Swiss3T3 ﬁ  -
broblasts were serum starved (SV) for 24 h 
followed by serum stimulation (SM) with 20% 
FBS for the indicated times, and fractionated 
lysates were immunoblotted with the indicated 
antibodies. Phospho-AKT (S473) and phospho-
AKT (T308) were blotted as controls for 
the effectiveness of the indicated treatments. 
Total lysates (top, M + C) were analyzed as 
controls for tuberin levels. Tuberin protein lev-
els within the membrane and cytosolic frac-
tions were determined as the percentage of 
total tuberin detected within both fractions. 
A representative blot from two independent 
biological replications is shown. Quantitation 
obtained from quintuplicate runs (n = 5) from 
each biological replicate is shown below. 
  (asterisks) Both the reduction in the membrane 
fraction and increase in cytosolic fraction of 
tuberin that occurred in response to serum 
stimulation for 1 h were signiﬁ  cantly different 
than starvation controls (t test, P < 0.02) and 
the 6 h time point (t test, P < 0.01). (D, top) Western analyses of tuberin from membrane and cytosolic fractions of serum-starved MCF7 cells (24 h) that 
were stimulated for 1 h with 30 ng/ml IGF-1 in the absence or presence of 100 nM of the PI3K inhibitor wortmannin. The vertical line indicates non-
adjacent lanes in a single blot. (bottom) Tuberin protein levels within the membrane and cytosolic fractions were determined as the percentage of total 
  tuberin detected within both fractions. A representative blot from three independent biological replications is shown. Quantitation is obtained from a to-
tal of seven independent Western blots from the three experiments. (asterisks) Both the reduction in the membrane fraction and increase in cytosolic frac-
tion of tuberin that occurred in response to IGF-1 stimulation were signiﬁ  cantly different from starvation controls (t test, P < 0.01) and the + wortmannin 
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the   cytosolic fraction is hyperphosphorylated.  In addition, the 
serum-induced decrease in mobility of tuberin in both membrane 
and cytosolic fractions is likely driven by multiple phosphoryla-
tion events, as CIAP treatment (removing all Ser/Thr phosphor-
ylation) increased the mobility of tuberin in both fractions.
To determine whether growth factor stimulation could 
also alter tuberin phosphorylation and subcellular localization, 
Swiss3T3 or MCF7 cells were serum starved and then stimu-
lated with serum or insulin-like growth factor-1 (IGF-1) before 
fractionation (Fig. 1, C and D; and Fig. S1, available at http://
www.jcb.org/cgi/content/full/jcb.200507119/DC1), as were 
NIH3T3 (Fig. S1 A) and TRKE2 cells (Fig. S1 B). Like serum, 
IGF-1 increased the amount of tuberin in the cytosolic fraction 
relative to starvation conditions (Fig. 1, C and D). In serum-
stimulated cells, phosphorylation of membrane-localized tu-
berin was also increased after 1 h (comparable to cytosolic 
tuberin in starved cells but less than cytosolic tuberin from serum-
stimulated cells; Fig. 1 C), suggesting that phosphorylation at 
specifi  c residues, rather than total levels of phosphorylation, 
was determining localization. By 6 h, tuberin became predomi-
nantly membrane localized, which correlated with a decrease in 
AKT activation (Fig. 1 C). Translocation of tuberin from the 
membrane to the cytosol was blocked by the PI3K inhibitors 
wortmannin and LY294002 (Fig. 1 D and Fig. S1 B), implicat-
ing PI3K signaling in tuberin localization to the cytosol.
Tuberin translocation is mediated 
by AKT phosphorylation
To determine whether AKT directed tuberin’s subcellular local-
ization, tuberin from membrane and cytosolic compartments of 
NIH3T3 cells treated with IGF-1 or EGF was immunoprecipi-
tated and detected with a (S/T) phosphosubstrate antibody that 
recognizes the consensus phosphorylation site for AKT and RSK 
containing phospho-Ser/Thr with Arg at position −5 and −3 
(RXRXXpS/T) (Alessi et al., 1996; Obata et al., 2000; Yaffe 
et al., 2001; Roux et al., 2004). With equal tuberin loading (Fig. 2, 
A and B), the (S/T) phosphosubstrate antibody predominantly 
recognized tuberin within the cytosolic fraction, and the PI3K 
inhibitor wortmannin signifi  cantly reduced recognition of phos-
phorylated tuberin, suggesting that cytosolic tuberin was phos-
phorylated by AKT (Fig. 2, A and B). To confi  rm that activation 
of AKT directed tuberin to the cytosol, MCF7 cells stably trans-
fected with a constitutively active AKT (myr-AKT) were exam-
ined and found to contain more cytosolic tuberin relative to 
wild-type MCF7 cells (Fig. 2 C). Recently, RSK was shown to 
phosphorylate tuberin at S1798 (Roux et al., 2004). To deter-
mine whether RSK phosphorylation of tuberin could regulate 
its localization, we generated a COOH-terminal deletion mutant 
of TSC2 at residue 1734 (referred to as ∆73) that lacks S1798 
(Roux et al., 2004). ∆73 and wild-type tuberin had a similar 
distribution within membrane and cytosolic fractions under 
  normal growth conditions (Fig. S1 C) and in response to serum 
(Fig. S2 A, available at http://www.jcb.org/cgi/content/full/
jcb.200507119/DC1). In addition, overexpression of RSK1 did 
not affect localization of wild-type tuberin (Fig. S2 B). Collec-
tively, these data indicate that tuberin residing in the cytosol is 
phosphorylated by AKT, suggesting that AKT (but not RSK) 
directly controls tuberin’s localization and possibly its activity.
Mutation of AKT phosphorylation sites 
in tuberin alters its localization
Tuberin contains multiple S/T phosphorylation sites (Fig. 3 A). 
Among these, S1254 has been shown to be phosphorylated by 
MK2 (Li et al., 2003), whereas S939 (Inoki et al., 2002; 
Figure 2.  AKT-mediated phosphorylation of tuberin leads to subcellular translocation. (A) NIH3T3 cells were treated with 100 ng/ml EGF in the absence 
or presence of 200 nM wortmannin for 1 h. The fractionated cell lysates were immunoprecipitated with an anti-tuberin antibody (N19) followed by Western 
blot analysis with an anti–phospho-(S/T) AKT substrate antibody and an anti-tuberin antibody (C20). (B) NIH3T3 cells were serum starved for 24 h followed 
by treatment with 30 ng/ml IGF-1 in the absence or presence of 100 nM wortmannin for 1 h. The fractionated cell lysates were immunoprecipitated with 
an anti-tuberin antibody (N19) followed by Western blot analysis with an anti–phospho-(S/T) AKT substrate antibody and an anti-tuberin antibody (C20). 
Phospho-AKT (S473) was blotted as a control for the effectiveness of the indicated treatments. The vertical line indicates nonadjacent lanes in a single blot. 
(C) Western analyses of tuberin, AKT, and phospho-AKT (S473) were performed using membrane and cytosolic fractions from wild-type MCF7 and MCF7 
cells that were stably transfected with constitutively active AKT (Myr-AKT). β1-integrin and LDH proteins were used as fractionation controls.JCB • VOLUME 173 • NUMBER 2 • 2006  282
Manning et al., 2002), S981 (Dan et al., 2002), S1130/S1132 
  (Inoki et al., 2002), and T1462 (Inoki et al., 2002; Manning et al., 
2002) have been reported to be AKT phosphorylation sites in vivo 
and/or in vitro, and several of these also have the potential for 
binding to 14-3-3 (http://scansite.mit.edu; Yaffe et al., 2001). S981 
is of particular interest, as it lies within the alternatively spliced 
exon 25 of tuberin. To examine these as candidate sites for the 
regulation of tuberin localization, we mutated these residues to 
alanine to create TSC2 constructs in frame with an NH2-terminal 
Flag epitope (Flag-TSC2): S939A, S981A, and 2A (S939A + 
S981A); T1462A and SATA (S939A + T1462A; Manning et al., 
2002); and S1254A and S1130A + S1132A double mutant.
Wild-type and mutant TSC2 constructs were transfected 
into HEK293 cells and subjected to subcellular fractionation. 
As shown in Fig. 3 (B and C), S939A, S981A, and 2A mutants 
predominantly localized to the membrane, as did the double 
  alanine SATA mutant that lacks the S939 site. However, the 
T1462A single mutant partitioned in the cell similarly to wild-
type tuberin (Fig. 3 B), indicating that T1462 phosphorylation 
was not directing translocation of tuberin from the membrane to 
the cytosol. These data were confi  rmed with a phosphospecifi  c 
T1462 antibody, which recognized tuberin in both the mem-
brane and cytosolic fractions equally (unpublished data). 
Furthermore, phosphorylation at both S939 and S981  contributes 
to cytosolic localization, as phosphorylation at S939   (determined 
with a phospho-S939 specifi  c antibody) of the S981A mutant 
was not suffi  cient to partition tuberin to the cytosol (Fig. S2 C). 
Other tuberin mutants, S1254A, S1130A/S1132A (Fig. 3 C), 
∆73, or S1338A (Fig. S1 C), also distributed equally between 
the membrane and cytosolic fractions. Thus, S939 and S981 
phosphorylation are critical determinants of membrane versus 
cytosolic localization of tuberin.
14-3-3 proteins mediate translocation 
of tuberin into the cytosol
14-3-3 has been previously reported to directly interact with 
phosphorylated tuberin (Li et al., 2002; Nellist et al., 2003). 
S939 and S981 are predicted AKT phosphorylation and 14-3-3 
interaction sites. When phosphorylated and nonphosphorylated 
S939 and S981 peptides were used in competition assays to 
block GST–14-3-3 interaction with tuberin, as shown in Fig. 4 A 
and Fig. S3 (available at http://www.jcb.org/cgi/content/full/
jcb.200507119/DC1), phosphorylated but not nonphosphory-
lated S939 and S981 peptides clearly competed for the inter-
action of tuberin with several 14-3-3 isoforms. In addition, the 
amount of 2A mutant tuberin affi  nity purifi  ed by 14-3-3 was 
dramatically reduced relative to wild-type tuberin (Fig. 4 B). 
Importantly, inhibition of PI3K signaling by wortmannin ab-
lated this 14-3-3 tuberin interaction (Fig. 4 B). These data indi-
cate that S939 and S981 are critical sites of interaction between 
tuberin and 14-3-3 proteins and that this interaction is mediated 
by PI3K/AKT phosphorylation.
To demonstrate that tuberin binding to 14-3-3 was directly 
responsible for its translocation to the cytosol, we transfected 
HEK293 cells with the EGFP-R18 construct that expresses a 
peptide that disrupts 14-3-3 binding (Jin et al., 2004). As shown 
in Fig. 4 C, the R18 14-3-3 decoy clearly repressed cytosolic 
localization of tuberin, establishing a direct link between 14-3-3 
and translocation of tuberin to the cytosol.
Hamartin enhances tuberin retention 
at the membrane
Hamartin possesses a predicted transmembrane domain and 
two coiled-coil domains that mediate its association with tu-
berin (van Slegtenhorst et al., 1997, 1998). We found that in 
both human and mouse cells, hamartin was only detected in the 
membrane fraction (Fig. 5, A and B; Fig. 3 B; unpublished 
data). To confi  rm that tuberin mutants that did or did not consti-
tutively localize to the membrane retained their ability to bind 
hamartin, immunoprecipitation experiments were performed. 
Immunoprecipitation showed that, similar to wild-type tuberin, 
tuberin S939A, S981A, S1338A, ∆73, and 2A mutants retained 
their ability to interact with hamartin (Fig. S4, A, B, and C, avail-
able at http://www.jcb.org/cgi/content/full/jcb.200507119/DC1). 
To determine whether hamartin played a role in the subcel-
lular localization of tuberin, we transfected wild-type, S939A, 
Figure 3.  Identiﬁ  cation of S939 and S981 as phosphorylation sites that 
determine tuberin localization. (A) Schematic of tuberin phosphorylation 
sites with Flag-TSC2 constructs and their corresponding mutations listed 
  below. (B) Western analysis of HEK293 membrane and cytosolic fractions 
using an anti-Flag antibody after transfection with wild-type and mutant 
Flag-TSC2 constructs. (C) Wild-type and mutant Flag-TSC2 constructs were 
overexpressed in HEK293 cells, and the membrane and cytosol lysates 
were immunoblotted with an anti-Flag antibody. The vertical line indicates 
nonadjacent lanes in a single blot.REGULATION OF TUBERIN BY INTRACELLULAR SHUTTLING • CAI ET AL. 283
and S981A Flag-TSC2 constructs into HEK293 cells with 
or without Myc- or Flag-TSC1. Although S939A and S981A 
mutants were primarily membrane localized, coexpression of 
hamartin increased membrane retention of both mutant and 
wild-type tuberin in a dose-dependent manner (Fig. 5, A and B). 
These data suggest that the interaction of hamartin with 
tuberin facilitates its localization to the membrane, implying 
that the tuberin–hamartin heterodimer functions in this sub-
cellular compartment.
Importantly, only tuberin in the membrane fraction re-
mained associated with hamartin: no hamartin could be co-
immunoprecipitated with tuberin in the cytosolic fraction, 
indicating that translocation to the cytosol dissociated tuberin 
from hamartin (Fig. 5 C). Similarly, when Flag-TSC2 and 
Myc-TSC1 were cotransfected into MCF7 cells, tuberin and 
  hamartin were observed by confocal microscopy to colocalize 
in a discrete, punctate pattern (Fig. S4 D). Cells that expressed 
wild-type Flag-TSC2 in the absence of Myc-TSC1 exhibited a 
more diffuse staining pattern than cells that overexpressed both 
Myc-TSC1 and Flag-TSC2 (Fig. S4 D, comparing γ and γ′ with 
β and β′). However, the 2A mutant, which was   constitutively 
membrane localized as shown by cell fractionation, retained 
this punctate localization pattern even in the absence of exoge-
nously expressed hamartin (Fig. S4 E).
Colocalization of tuberin and Rheb 
is disrupted in response to growth 
factor stimulation
Tuberin’s GAP target Rheb is farnesylated and predicted to be 
membrane localized (Clark et al., 1997), and recent data   indicate 
Figure 4.  14-3-3 proteins bind and sequester 
tuberin in the cytosol. (A) GST–14-3-3 proteins 
were used to afﬁ   nity purify proteins from 
HEK293 cells in the presence of phosphory-
lated or nonphosphorylated S939 and S981 
tuberin peptides. Afﬁ  nity-puriﬁ  ed  complexes 
were immunoblotted to detect the amount of tu-
berin interacting with 14-3-3. The vertical line 
indicates nonadjacent lanes in a single blot. 
(B) HEK293 cells were transfected with Flag-
TSC2-WT or Flag-TSC2-2A in the absence or 
presence of 200 nM wortmannin. Western 
analysis of exogenous tuberin was performed 
after using GST–14-3-3 proteins to afﬁ  nity purify 
Flag-tuberin. (C) HEK293 cells were transfected 
with Flag-TSC2 in the presence or absence of 
GFP-R18 14-3-3 decoy expression construct, 
and fractionated lysates were used for Western 
analyses with the indicated antibodies. LDH 
was used as a fractionation control.
Figure 5.  Hamartin increases the amount of 
tuberin retained in the membrane. (A) HEK293 
cells were transfected with wild-type and mu-
tant Flag-TSC2 constructs in the presence or 
absence of a Myc-TSC1 construct. Cells were 
fractionated and immunoblotted with indicated 
antibodies. (B) HEK293 cells were transfected 
with wild-type TSC2 constructs along with in-
creasing amounts of Flag-TSC1. Cells were 
then fractionated and immunoblotted with indi-
cated antibodies. (C) HEK293 cells were 
  transfected with Flag-TSC2 and Myc-TSC1 
constructs. The fractionated cell lysates were 
immunoprecipitated with an anti-Flag antibody 
followed by Western analysis with anti-Flag 
(mouse) and anti-Myc (mouse). The same blot 
was then reprobed with anti-tuberin (rabbit) 
and anti-hamartin (rabbit) as indicated.JCB • VOLUME 173 • NUMBER 2 • 2006  284
that Rheb is localized in endomembranes (Takahashi et al., 
2005). To determine whether phosphorylation at S939/S981 
affected tuberin’s intrinsic GAP activity for Rheb, we fi  rst de-
termined Rheb’s subcellular localization. Rheb was detected 
only in the membrane fractions from HEK293 (Fig. 3 B) and 
MCF7 (Fig. S5 A, available at http://www.jcb.org/cgi/content/
full/jcb.200507119/DC1) as well as NIH3T3, Swiss3T3, and 
TRKE2 cells (not depicted). Treatment with EGF or wortmannin 
did not affect this localization over a period of 10 min to 3 h 
(Fig. S5 A and not depicted). Recognition of the 21-kD band in 
the membrane fraction using this anti-Rheb antibody was spe-
cifi  c for Rheb, as antibody binding was ablated when Rheb 
RNAi was used to knock down Rheb (Fig. S5 B). When un-
tagged TSC1/Flag-TSC2 and Myc-Rheb were cotransfected into 
HeLa cells, tuberin and Rheb were observed with confocal 
  microscopy to colocalize in a discrete, punctate pattern in the 
absence of serum (Fig. 6). In contrast, stimulation with IGF-1 
resulted in partitioning of wild-type tuberin away from Rheb 
(Fig. 6), indicating that in response to growth factor stimulation, 
tuberin is no longer retained in physical proximity to its down-
stream target, Rheb. Collectively, these data indicate that the 
  localization pattern of tuberin is modulated by both hamartin 
and growth factor signaling and that Rheb is in physical prox-
imity to membrane-localized tuberin and hamartin within the 
cell. In addition, these data, along with confocal microscopy 
  using 2A mutant tuberin and biochemical fractionation, sug-
gest that S939 and S981 are crucial sites for determining the 
sub  cellular localization and, thus, function of tuberin in re-
sponse to growth factor signaling.
Tuberin localization regulates its function
To elucidate the relationship between tuberin localization and 
function, we examined the effect of wild-type, S939A, S981A, 
and 2A tuberin mutants on mTOR-S6K activity. T389 is a 
known rapamycin-sensitive phosphorylation site of S6K that 
correlates with activation by mTOR (Pearson et al., 1995). 
In  cells transfected with HA-tagged S6K, cotransfection of 
wild-type TSC1 and -2 expression constructs diminished phos-
phorylation of exogenously expressed S6K (Fig. 7 A). However, 
cotransfection of the 2A mutant with TSC1 resulted in an even 
more dramatic reduction in phospho-S6K levels (Fig. 7 A). 
Similar experiments were performed to determine the effect of 
S939A and S981A single and double mutants on phosphoryla-
tion of endogenous S6K. In the presence of serum, wild-type 
Flag-tuberin was located in the membrane and cytosol, whereas 
S939A, S981A, and 2A Flag-tuberin mutants remained primar-
ily at the membrane (Fig. 7 B, top). AKT was equally activated 
by serum in cells expressing wild-type or mutant tuberin con-
structs, and endogenous hamartin remained membrane local-
ized (Fig. 7 B). In cells transfected with wild-type tuberin, 
phosphorylation of endogenous S6K at T389 increased in re-
sponse to serum, coincident with translocation of tuberin to the 
cytosol. However, in cells transfected with S939A, S981A, or 
2A tuberin mutants, phosphorylation of S6K was inhibited, 
with the 2A mutant most effectively blocking S6K activation 
(Fig. 7 B). Thus, tuberin mutants that were retained at the mem-
brane were constitutively active and exhibited enhanced ability 
to repress S6K activation. These data suggest that AKT phos-
phorylation of tuberin regulates its activity by decreasing the 
amount of tuberin located at the membrane, thereby reducing its 
inhibitory effect on the Rheb–mTOR–S6K signaling pathway.
Phosphorylation sites that determine 
localization and function of tuberin 
do not change its intrinsic RhebGAP 
activity in vitro
Physical sequestration of tuberin from its target Rheb suggested 
a mechanism whereby AKT modulated tuberin by partitioning 
it away from the membrane rather than altering its intrinsic 
GAP activity for Rheb. We compared the relative RhebGAP 
  activity of wild-type TSC2 and 2A mutant (S939A and S981A) 
in cells during activation of the PI3K–AKT pathway (Fig. 8). 
Figure 6.  Tuberin colocalization with Rheb is 
disrupted in response to growth factor stimula-
tion. HeLa cells were transfected in serum-free 
media with Flag-TSC2 WT and Myc-Rheb 
along with an untagged TSC1 construct. After 
12 h without serum, cells were treated with 
30 ng/ml IGF-1 for 1 h. Localization of exoge-
nous Flag-tuberin (green) and Myc-Rheb (red) 
was detected by double immunoﬂ  uorescence 
labeling and confocal microscopy. Colocaliza-
tion is detected in the merged image with the 
yellow signal (right).REGULATION OF TUBERIN BY INTRACELLULAR SHUTTLING • CAI ET AL. 285
To do this, we quantifi  ed the ratio of GTP and GDP Myc-Rheb 
(percentage of GTP bound Myc-Rheb) when these TSC2 con-
structs were coexpressed during a time course of insulin 
  stimulation. The 2A mutant enhanced the GTPase function of 
Rheb more effectively than wild-type tuberin, as indicated by 
impaired accumulation of the active GTP form of Rheb after 
15 min of insulin stimulation (32% GTP bound) when   compared 
with wild-type TSC2 (42% GTP bound; Fig. 8 A). As an in-
crease in GTP bound Rheb would be predicted to enhance 
mTOR-mediated cell signaling, we measured the   activity of 
HA-S6K1 in these cells (Fig. 8 B). As expected,   insulin-induced 
activation of S6K1 was markedly impaired in cells expressing 
the 2A mutant with the 2A mutant blocking   insulin-induced ac-
tivation of S6K1 by 50% (after 15 min) when compared with 
wild-type TSC2 (Fig. 8 B), refl  ecting the reduced levels of ac-
tive GTP bound Rheb (Fig. 8 A).
To determine whether phosphorylation at S939 and S981 
had an impact on tuberin’s intrinsic GAP activity, we analyzed the 
ability of wild-type or mutant tuberin proteins to activate Rheb 
GTPase in vitro. RhebGAP assays were conducted on immuno-
precipitated tuberin–hamartin heterodimers containing either 
the wild-type or AKT-phosphorylation mutants of TSC2 (Fig. 9). 
Figure 8.  AKT phosphorylation of tuberin promotes Rheb-induced S6K1 
activation through increased Rheb-GTP loading. (A) HEK293 cells co-
expressing HA-S6K1, Myc-Rheb, Flag-TSC1, and either Flag-TSC2-WT or 
Flag-TSC2-2A (S939A and S981A) were serum starved and, where indi-
cated, the PI3K–AKT signaling pathway was stimulated with 100 nM insu-
lin for 7.5 and 15 min. These cells were subjected to in vivo radiolabeling, 
and the level of guanine nucleotide bound to immunoprecipitated Myc-
Rheb was quantiﬁ  ed. A representative blot from three independent biologi-
cal replications is shown. The mean of the percentage of total Myc-Rheb 
bound to GTP (active state) is shown in the bar ﬁ   gure. (B) In parallel, 
HEK293 cells treated as in A were subjected to S6K1 activity assays. 
HA-S6K1 used in the activity assay was analyzed with an anti-HA antibody. 
32P-  incorporation into GST-S6 substrate was quantiﬁ  ed using a phospho-
rimager, and the fold activation of S6K1 is graphed. Protein levels of Flag-
TSC1, Flag-TSC2, and AKT, and level of AKT phosphorylation at S473, 
were determined using Western analyses.
Figure 7.  AKT-mediated phosphorylation of tuberin relieves repression of 
mTOR-S6K signaling. (A) HEK293 cells were transfected with HA-S6K, 
Myc-TSC1, and Flag-TSC2 constructs as indicated. Cells were serum 
starved for 24 h and treated with or without 30 ng/ml IGF-1 for 1 h. Cell 
lysates were immunoblotted with the indicated antibodies, and phopho-
S6K levels were compared with the amount of HA-S6K protein levels. 
  Phospho-AKT (S473) was blotted as a control for the effectiveness of IGF-1 
treatment. (B) Western analyses of membrane and cytosolic fractions from 
HEK293 cells transfected with wild-type or mutant Flag-TSC2 constructs. 
After 9 h, serum was either removed or allowed to remain for 24 h. The 
protein levels of phosphorylated endogenous S6K were compared with 
  total S6K protein levels. Phospho-AKT (S473) and phospho-AKT (T308) 
were blotted as controls for the effectiveness of the indicated treatments.JCB • VOLUME 173 • NUMBER 2 • 2006  286
Tuberin–hamartin complexes containing wild-type tuberin from 
both unstimulated and insulin-stimulated cells enhanced the in-
trinsic GTPase activity of Rheb at comparable rates. Induction 
of tuberin phosphorylation by insulin was confi  rmed in these 
lysates by detection of phospho-T1462 (Fig. 9, bottom). 
  Furthermore, tuberin mutants lacking these sites (S939A, 
S981A, and 2A) also possessed similar RhebGAP activity to 
wild-type tuberin in vitro, even after insulin treatment (Fig. 9). 
These fi  ndings imply that AKT-mediated phosphorylation of 
tuberin does not directly alter the rates at which tuberin en-
hances the GTPase activity of Rheb, at least in vitro. However, 
these data support a mechanism whereby AKT phosphorylation 
suppresses tuberin function by translocating tuberin to the cyto-
sol away from its membrane-associated binding partner, hamar-
tin, and its downstream target, Rheb. Indeed, as the effi  ciency 
with which tuberin functions as a RhebGAP in vitro is signifi  -
cantly reduced in the absence of hamartin, physical separation 
from both hamartin and Rheb may be contributing to reduced 
tuberin activity (Tee et al., 2002; Li et al., 2004b).
A mechanism by which tuberin function 
is regulated through subcellular localization
Based on our data, we propose a model where in the absence of 
growth stimulatory signals, hamartin facilitates localization of 
hypophosphorylated tuberin to membranes in physical proxim-
ity to Rheb. The membrane-associated tuberin–hamartin com-
plex binds Rheb and acts as a GAP to inactivate membrane 
Rheb signaling by stimulating GTP hydrolysis (Fig. 10 A). 
However, during mitogenic suffi  ciency (i.e., after growth factor 
stimulation), activation of PI3K signaling leads to activation of 
AKT, which then directly phosphorylates membrane-associated 
tuberin. In response to AKT phosphorylation, 14-3-3 proteins 
bind tuberin and sequester it in the cytosol. The defi  ciency of 
membrane-associated tuberin results in the accumulation of 
GTP bound Rheb, which leads to increased mTOR signaling, 
enhanced cell growth, and proliferation (Fig. 10 B).
Discussion
In this study, we provide evidence that AKT inhibits the tumor 
suppressor function of tuberin by altering its subcellular 
  localization. Previously, AKT was shown to directly phosphorylate 
and inhibit tuberin function upon stimulation with growth fac-
tors (Marygold and Leevers, 2002). However, it was not known 
how AKT phosphorylation of tuberin regulated its function or 
how hamartin contributed to tuberin regulation of Rheb and 
mTOR (Garami et al., 2003; Tee et al., 2003; Zhang et al., 
2003). We have shown that although tuberin is found in both the 
membrane and cytosolic fractions of cells, cytosolic tuberin ac-
cumulates upon growth factor stimulation and is hyperphos-
phorylated. The translocation of tuberin from the membrane 
to the cytosol can be blocked by PI3K inhibitors, and AKT-
  phosphorylated tuberin is predominantly found in cytosolic 
fractions. The AKT phosphorylation sites S939 and S981 are 
Figure 9.  Tuberin’s GAP activity for Rheb in vitro is not affected by AKT 
phosphorylation. HEK293 cells coexpressing Flag-TSC1 and Flag-TSC2-
WT, Flag-TSC2-S939A, Flag-TSC2-S981A, or Flag-TSC2-2A were serum 
starved and then stimulated with 100 nM insulin for 30 min. TSC1 and -2 
were immunoprecipitated from the lysates and subjected to RhebGAP activ-
ity assays for 15, 30, or 60 min. Immunocomplexes containing wild-type 
and mutant tuberin activated Rheb similarly, as indicated by quantitation of 
percentage of GDP. The vertical line indicates nonadjacent lanes resolved 
on a single thin layer chromatography plate. For quality control of the 
α-[
32P]GTP used in the assay, the guanine nucleotide eluted from the 60-min 
vector control was resolved on a separate thin layer chromatography plate 
and shows that Rheb is 98% bound to GTP in the absence of hamartin and 
tuberin. Each assay contained approximately equal amounts of TSC1 and -2, 
and AKT activation was conﬁ   rmed with a phospho-T1462 antibody by 
Western blot analysis (bottom).
Figure 10.  Model for regulation of tuberin under conditions of mitogenic 
sufﬁ  ciency. (A) Tuberin normally functions as a GAP for Rheb within an in-
tracellular membrane compartment, inhibiting Rheb and mTOR signaling, 
which suppresses cell growth. (B) Upon stimulation by growth factors, AKT 
is activated, leading to phosphorylation and cytosolic sequestration of 
  tuberin by 14-3-3 proteins. This cytosolic translocation relieves tuberin 
  repression of the Rheb-mTOR signaling, stimulating cell growth.REGULATION OF TUBERIN BY INTRACELLULAR SHUTTLING • CAI ET AL. 287
crucial residues that affect tuberin localization, with localiza-
tion of tuberin to the membrane accounting for the ability of tu-
berin to inhibit mTOR signaling via its GAP activity for Rheb.
We show that two tuberin phosphorylation sites, S939 
and S981, are responsible for interaction with 14-3-3 in a 
  phosphorylation-dependent manner. 14-3-3 proteins are highly 
acidic dimeric intracellular proteins that chiefl  y bind to phos-
phoserine motifs (Yaffe and Elia, 2001). They play a key reg-
ulatory role in many cellular processes, including signal 
transduction, apoptosis, and cell cycle checkpoint control 
(
 Muslin and Xing, 2000; Tzivion et al., 2001; Yaffe, 2002; 
  Hermeking, 2003). In many instances, 14-3-3 binding leads to 
altered subcellular localization of target proteins, which modu-
lates their function. As this appears to be the case for tuberin as 
well, we propose a mechanism whereby growth factor stimula-
tion activates AKT, leading to tuberin phosphorylation and 
  mislocalization within the cell. Although some studies have 
suggested that the tuberin–hamartin heterodimer is destabilized 
upon AKT-mediated phosphorylation of tuberin (Inoki et al., 
2002; Potter et al., 2002), our data and those of others indicate 
that AKT-mediated phosphorylation of tuberin does not change 
its affi  nity for hamartin (Dan et al., 2002; Manning et al., 2002; 
Tee et al., 2003). An alternative hypothesis is that in response to 
phosphorylation of S939 and S981 by AKT, 14-3-3 binds to 
these phosphorylated motifs to localize tuberin in the cytosol, 
physically sequestering tuberin away from hamartin. The pres-
ence of two adjacent 14-3-3 binding sites at S939 and S981 of 
tuberin may be important, as they would be predicted to stabi-
lize binding of tuberin in the central channel of the 14-3-3 dimer 
more effectively than would a single binding site.
In this regard, it is interesting that loss of either the S939 
or S981 14-3-3 binding sites reduces localization of tuberin to 
the cytosol. As one of these binding sites is in the alternatively 
spliced exon 25 of tuberin, it suggests that alternative splicing 
may allow for wider or more varied regulation of this tumor 
suppressor. In splice isoforms lacking exon 25, the absence of 
the S981 binding site could result in retention at the membrane, 
potentially enhancing tuberin activity. This could provide a 
mechanism via alternative exon splicing for cells and tissues to 
regulate tuberin localization and function. It might be noted that 
in previous studies that failed to identify the S939 site within 
tuberin as a 14-3-3 binding site, the TSC2 construct used lacked 
the alternatively spliced exon 25 and the S981 14-3-3 binding 
site (Li et al., 2002).
Hamartin has been shown to signifi  cantly  enhance 
  tuberin’s GAP activity toward Rheb GTPase (Garami et al., 
2003; Tee et al., 2003), and our observations also emphasize the 
importance of the interaction between tuberin and hamartin as a 
functional unit. We found that hamartin directly interacts with 
tuberin and promotes tuberin colocalization at the membrane in 
proximity to its GAP target Rheb and enhances tuberin’s ability 
to repress mTOR signaling. Both endogenously and exoge-
nously expressed hamartin were detected in the membrane frac-
tion of cells, even when cells were treated with serum or growth 
factors, data that are consistent with the previous reports that 
hamartin is a membrane protein (van Slegtenhorst et al., 1997; 
Plank et al., 1998). The colocalization of tuberin in proximity to 
its activation partner hamartin and its GAP target Rheb at the 
membrane could explain why increased retention of tuberin at 
the membrane enhances its ability to inhibit phosphorylation of 
S6K. Given that the S939 and S981 residues lie distal from the 
COOH-terminal GAP region (residues 1517–1674) of tuberin 
and mutation of these sites does not affect the Rheb GAP activ-
ity of tuberin, we conclude that phosphorylation of S939 and 
S981 does not directly regulate the GAP function of TSC2. 
However, mutation of these sites signifi  cantly inhibits Rheb-
  induced S6K1 activation through decreased Rheb-GTP load-
ing, suggesting that AKT regulates tuberin function by causing 
tuberin translocation to the cytosol, rather than by directly in-
hibiting its intrinsic GAP activity toward Rheb.
Materials and methods
Antibodies and reagents
The following antibodies were used: tuberin, hamartin, lamin A/C, HA, 
and Myc (Santa Cruz Biotechnology, Inc.); Rheb, phosphotuberin (T1462), 
S6K, phospho-S6K (T389), AKT, phospho-AKT (S473), phospho-AKT 
(T308), and phospho-(S/T) AKT substrate (Cell Signaling Technology); Flag 
M2 and Flag M2 immobilized agarose beads (Sigma-Aldrich); LDH 
(Chemicon International); EGFP (Abcam); and β1-integrin (CLONTECH 
Laboratories, Inc.). The following reagents were used: EGF, insulin, and 
wortmannin (Sigma-Aldrich) and IGF-1 (R & D Systems). Tuberin peptides 
were synthesized by W.M. Keck Biotechnology Resource Center.
Constructs
Full-length human TSC1 and -2 cDNAs (supplied by J. DeClue, National 
Cancer Institute, Bethesda, MD) were subcloned into pcDNA3.1 (Invitro-
gen) and pCMV-Tag2 (Stratagene) expression vectors with NH2-terminal 
Myc or Flag epitopes, respectively. COOH-terminal truncation mutant 
of TSC2 (∆73) (residues 1–1734) was created by EcoR V digestion fol-
lowed by religation. TSC2 mutations were generated by site-directed 
  mutagenesis (Stratagene).
Other constructs used in this study were generously provided as 
  follows: Flag-TSC1 and HA-S6K from J. Blenis (Harvard Medical School, 
Boston, MA), HA-RSK1 from J. Avruch (Massachusetts General Hospital, 
Boston, MA), GFP-R18 from T. Pawson (Mount Sinai Hospital, Toronto, 
Canada), and the Flag-TSC2 SATA and T1462A from B. Manning 
(Harvard School of Public Health, Boston, MA). GST–14-3-3 constructs 
were described previously (Liu et al., 2002).
Cell culture, transfection, and immunoprecipitation
Cell lines were grown as follows: MCF7 cells were grown in improved mini-
mum essential medium (Biosource International). TRKE2 cells were grown in 
DF8 complete medium (Walker and Ginsler, 1992). HeLa cells were grown 
in MEM, and HEK293, Swiss3T3, and NIH3T3 cells were grown in DME 
(Life Technologies, Inc.). All media contained 10% FBS (Hyclone) unless 
otherwise noted. Myr-Akt MCF7 cells were cultured as previously described 
(DeGraffenried et al., 2003). Transfections were performed using the Lipo-
fectamine 2000 reagent (Invitrogen) according to manufacturer’s instructions. 
Cells were lysed using PBS containing 0.1% SDS, 1% NP-40, 0.5% deoxy-
cholic acid, 1 μM PMSF, 20 μg/ml aprotinin, 10 μM leupeptin, and 1 μM 
Na3VO4. For immunoprecipitation, cell lysates were immunoprecipitated 
with the indicated antibodies and protein A– or protein G–Sepharose 
beads (GE Healthcare) and washed with buffer (10 mM Tris-HCl, pH 7.5, 
1% NP-40, 1% Triton X-100, 100 mM NaCl, 50 mM NaF, 2 mM EDTA, 
1 mM PMSF, and Complete protease inhibitor cocktail [Roche]). Immuno-
complexes were subjected to SDS-PAGE and Western blotting.
Subcellular fractionation and protein phosphatase treatments
Cells (70–80% conﬂ  uent in 15-cm plates) were washed and collected by 
scraping into ice-cold PBS, pelleted by centrifugation at 4°C, resuspended 
in hypotonic buffer (10 mM Hepes, pH 7.2, 10 mM KCl, 1.5 mM MgCl2, 
0.1 mM EGTA, 20 mM NaF, and 100 μM Na3VO4), and disrupted using 
a Dounce homogenizer. Crude nuclei and unbroken cells were then pel-
leted by centrifugation at 3,000 rpm at 4°C for 5 min. The postnuclear 
  supernatant was separated by ultracentrifugation at 100,000 g for 1 h at 
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was lysed in 1× lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 
1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM NA4P207, 1 mM 
β-glycerophosphate, 1 mM Na3VO4, and 1 μg/ml leupetin). The insoluble 
fractions were removed by centrifugation at 14,000 rpm for 10 min, and 
the supernatant was collected as the membrane fraction. Crude nuclei 
were resuspended with hypotonic buffer and homogenized using a Dounce 
homogenizer. After centrifugation at 4°C for 5 min, the pellet was further 
washed with wash buffer (10 mM Tris-HCl, pH 7.4, 0.1% NP-40, 0.05% 
sodium deoxycholate, 10 mM NaCl, and 3 mM MgCl2) and lysed in high-
salt lysis buffer (20 mM Hepes, pH 7.4, 0.5 M NaCl, 0.5% NP-40, and 
1.5 mM MgCl2). All lysis and wash buffers contained 1× Complete prote-
ase inhibitor cocktail. The nuclear, membrane, and cytosolic lysates were 
normalized using the BCA Protein Assay kit (Pierce Chemical Co.) and 
subjected to SDS-PAGE and immunoblot analysis. For phosphatase treat-
ment, equal amounts of membrane and cytosolic lysates were treated with 
CIAP serine/threonine phosphatase or YOP tyrosine phosphatase at 30°C 
for 1 h.
GST–14-3-3 pull-down assays
GST pull-down assays were performed as previously described (Liu et al., 
2002). For peptide competition assays, incubations were performed in the 
presence or absence of 100 μM phospho-Ser
939 or Ser
939 tuberin peptide 
(S  G  S  G  F  R  A  R  S  T  S   [939] LNERPK) or phospho-Ser
981 or Ser
981 tuberin peptide 
(S  G  S  G  F  R  C  R  S  I  S   [981] VSEHVV).
Rheb GAP and S6K1 assay
Anti-Flag M2 antibody was used to immunoprecipitate Flag-tuberin from 
HEK293E cells. Immunocomplexes of TSC1/TSC2 were used for in vitro 
RhebGAP assays as previously described (Tee et al., 2003). α-[
32P]GTP 
and α-[
32P]GDP were eluted from Rheb and resolved by thin layer chroma-
tography on PEI cellulose (Sigma-Aldrich) with KH2PO4. The relative levels 
of radiolabeled GTP and GDP were quantiﬁ  ed with a phosphorimager.
S6K1 activity assays on immunoprecipitated HA-S6K1 were performed 
as previously described (Martin et al., 2001) using recombinant GST-S6 
(32 COOH-terminal amino acids of ribosomal protein S6) as substrate.
In vivo Rheb nucleotide binding
Analysis of Rheb guanine nucleotide binding in cells was determined as 
previously described (Tee et al., 2005).
Immunoﬂ  uorescent staining
Intracellular localization of wild-type tuberin and 2A mutant and colocal-
ization studies was determined by immunoﬂ  uorescence analysis of HeLa 
cells. Transfected cells were plated onto glass chamber slides in the ab-
sence of serum. After 12 h of serum starvation, transfected cells were 
treated with either 20% FBS or 30 ng/ml IGF-1 for 1 h. Cells were then 
ﬁ  xed in 50% ethanol plus 10% acetic acid for 1 h at 4°C, and nonspeciﬁ  c 
antigens were blocked for 1 h in PBS containing 7.5% BSA at 37°C. 
  Rabbit anti-Flag (Sigma-Aldrich) and/or mouse anti-Myc (Santa Cruz 
Biotechnology, Inc.) primary antibodies were incubated in PBS/7.5% BSA 
at 37°C for 2 h. Primary antibodies were detected with FITC-conjugated 
goat anti–rabbit (Abcam) and Cy3-conjugated donkey anti–mouse (  Jackson 
ImmunoResearch Laboratories) antibodies, respectively.
Microscopy
Fluorescence images were analyzed either on a confocal microscope 
(Fluoview Scanning Laser Biological Microscope IX 70 system; Olympus) 
equipped with two lasers (Ar 488 and Kr-Ar 488–564) using UplanFl 
100× oil-immersion (NA 1.30) objective or a conventional microscope 
with ﬂ  uorescence attachment (BX40 attached with BX-FLA; Olympus) using 
UplanFl 40× (NA 0.75) objective. Fluoview version 1.26 software 
(  Olympus) and MagnaFire version 2.1C (Olympus) were used for image 
acquisition from confocal microscopy and conventional microscopy, 
  respectively. Photoshop 8.0 software (Adobe) was used for minor adjust-
ments and processing of images.
Online supplemental material
Fig. S1 shows that AKT-mediated phosphorylation of tuberin leads to sub-
cellular translocation. Fig. S2 shows that S939 and S981 are required for 
altered subcellular localization of tuberin. Fig. S3 demonstrates that 14-3-3 
proteins bind phosphorylated S939 and S981 residues. Fig. S4 demon-
strates that tuberin mutants retain their ability to interact with hamartin. Fig. 
S5 shows that Rheb is retained in the membrane fraction in the presence or 
absence of growth factor treatment. Online supplemental material is avail-
able at http://www.jcb.org/cgi/content/full/jcb.200507119/DC1.
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